8-K: Athira Pharma Reports Positive Phase 1 Data for ATH-1105 and First Quarter 2025 Financial Results

Athira Pharma announces completion of Phase 1 clinical study of ATH-1105 for ALS and reports Q1 2025 financial results, highlighting progress in pipeline development and strategic alternatives exploration.

Summary

• Athira Pharma reported its financial results for the quarter ended March 31, 2025, and provided updates on its pipeline and business.
• The company completed a Phase 1 clinical study of ATH-1105 in healthy volunteers as a potential treatment for amyotrophic lateral sclerosis (ALS).
• Full healthy volunteer data from the Phase 1 study is expected in the second half of 2025, with plans to enable dosing ALS patients in late 2025.
• The Phase 1 trial results showed that ATH-1105 demonstrated a favorable safety profile and was well-tolerated in healthy volunteers.
• Athira is exploring strategic alternatives to maximize stockholder value after the topline results of LIFT-AD did not meet its primary or key secondary endpoints in September 2024.
• Cash, cash equivalents, and investments were $36.7 million as of March 31, 2025, compared to $51.3 million as of December 31, 2024.
• Net cash used in operations was $14.7 million for the quarter ended March 31, 2025, compared to $25.8 million for the quarter ended March 31, 2024.
• Research and Development (R&D) expenses were $4.3 million for the quarter ended March 31, 2025, compared to $21.2 million for the quarter ended March 31, 2024.
• General and Administrative (G&A) expenses were $5.2 million for the quarter ended March 31, 2025, compared to $6.5 million for the quarter ended March 31, 2024.
• Net loss was $9.1 million, or $0.23 per share, for the quarter ended March 31, 2025, compared to a net loss of $26.3 million, or $0.69 per share, for the quarter ended March 31, 2024.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the promising Phase 1 data for ATH-1105 and the focus on ALS, but tempered by the exploration of strategic alternatives and reduced cash position.

Positives

• ATH-1105 demonstrated a favorable safety profile and was well-tolerated in healthy volunteers in the Phase 1 trial.
• The company is on track to enable dosing ALS patients with ATH-1105 in late 2025.
• Net loss decreased significantly year-over-year, from $26.3 million to $9.1 million.
• R&D and G&A expenses decreased year-over-year, indicating cost management.

Negatives

• The company is exploring strategic alternatives after the LIFT-AD trial did not meet its primary or key secondary endpoints.
• Cash, cash equivalents, and investments decreased from $51.3 million at the end of 2024 to $36.7 million as of March 31, 2025.
• The company experienced a net loss of $9.1 million for the quarter ended March 31, 2025.

Risks

• The development of ATH-1105 could face delays or setbacks.
• Regulatory authorities could object to protocols, amendments, or other submissions.
• The company's assumptions regarding its financial condition and the sufficiency of its cash may be incorrect.
• The exploration of strategic alternatives could lead to uncertain outcomes.
• The company faces risks related to competition and changing laws and regulations.

Future Outlook

Athira is focused on advancing ATH-1105 as a potential therapy for ALS and expects to share full results from the Phase 1 trial in healthy volunteers in the second half of 2025, with plans to enable dosing ALS patients in late 2025. The company is also exploring strategic alternatives to maximize stockholder value and partnering options.

Management Comments

• Mark Litton, Ph.D., President and Chief Executive Officer of Athira, stated that ATH-1105 has shown encouraging evidence of statistically significant improvements in nerve and motor function and biomarkers of inflammation and neurodegeneration in preclinical models, along with a favorable safety profile and tolerability in healthy volunteers.
• He also mentioned that the company looks forward to sharing the full results from the first-in-human Phase 1 trial of ATH-1105 in healthy volunteers in the second half of this year, keeping the company on-track to enable dosing ALS patients in late 2025.

Industry Context

Athira's focus on ATH-1105 for ALS aligns with the growing need for effective treatments for neurodegenerative diseases. The company's approach of targeting the neurotrophic HGF system is a novel strategy in the field. The exploration of strategic alternatives suggests a response to the challenges faced in Alzheimer's drug development, a common theme in the biopharmaceutical industry.

Comparison to Industry Standards

• The Phase 1 trial results showing a favorable safety profile for ATH-1105 are encouraging, as safety is a critical factor in early-stage drug development.
• Many companies such as Biogen, Ionis Pharmaceuticals, and Amylyx Pharmaceuticals are also developing treatments for ALS, making the competitive landscape intense.
• Athira's cash position of $36.7 million is relatively modest compared to larger pharmaceutical companies, which may impact its ability to fund extensive clinical trials and commercialization efforts.
• The decrease in R&D expenses reflects a strategic shift after the LIFT-AD trial results, which is a common response in the industry when faced with clinical trial setbacks.

Stakeholder Impact

• Shareholders may be impacted by the exploration of strategic alternatives.
• Employees are affected by the changes in R&D and G&A expenses, potentially leading to restructuring.
• Patients with ALS may benefit from the development of ATH-1105.
• The company's financial condition impacts its ability to engage with suppliers and creditors.

Next Steps

• Athira will present Phase 1 and nonclinical efficacy data for ATH-1105 at the 4th Annual ALS Drug Development Summit on May 13, 2025.
• The company expects to share full results from the Phase 1 trial of ATH-1105 in healthy volunteers in the second half of 2025.
• Athira plans to enable dosing ALS patients with ATH-1105 in late 2025.
• The company will continue to explore strategic alternatives to maximize stockholder value.

Key Dates

Keywords

ATH-1105, ALS, Amyotrophic Lateral Sclerosis, Clinical Trial, Phase 1, Financial Results, Neurodegenerative Diseases, Athira Pharma, Fosgonimeton, Strategic Alternatives